Bruce E. Sands

64.8k total citations · 22 hit papers
596 papers, 39.6k citations indexed

About

Bruce E. Sands is a scholar working on Genetics, Epidemiology and Surgery. According to data from OpenAlex, Bruce E. Sands has authored 596 papers receiving a total of 39.6k indexed citations (citations by other indexed papers that have themselves been cited), including 491 papers in Genetics, 346 papers in Epidemiology and 182 papers in Surgery. Recurrent topics in Bruce E. Sands's work include Inflammatory Bowel Disease (486 papers), Microscopic Colitis (315 papers) and Eosinophilic Esophagitis (83 papers). Bruce E. Sands is often cited by papers focused on Inflammatory Bowel Disease (486 papers), Microscopic Colitis (315 papers) and Eosinophilic Esophagitis (83 papers). Bruce E. Sands collaborates with scholars based in United States, Canada and France. Bruce E. Sands's co-authors include William J. Sandborn, Brian G. Feagan, Jean‐Frédéric Colombel, Paul Rutgeerts, Stephen B. Hanauer, Gary R. Lichtenstein, Silvio Danese, Walter Reinisch, Daniel H. Present and Joshua R. Korzenik and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Bruce E. Sands

540 papers receiving 38.8k citations

Hit Papers

Infliximab for Induction and Maintenance Therapy for Ulce... 1999 2026 2008 2017 2005 2013 2012 2013 1999 500 1000 1.5k 2.0k 2.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
    2005 2.9k citations Paul Rutgeerts, William J. Sandborn et al. New England Journal of Medicine profile →
  2. Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
    2013 2.0k citations Brian G. Feagan, Paul Rutgeerts et al. New England Journal of Medicine profile →
  3. Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment
    2012 2.0k citations Bruce E. Sands et al. profile →
  4. Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
    2013 2.0k citations William J. Sandborn, Brian G. Feagan et al. New England Journal of Medicine profile →
  5. Infliximab for the Treatment of Fistulas in Patients with Crohn's Disease
    1999 2.0k citations Stephen B. Hanauer, Bruce E. Sands et al. New England Journal of Medicine profile →
  6. Infliximab Maintenance Therapy for Fistulizing Crohn's Disease
    2004 1.6k citations Bruce E. Sands, Brian G. Feagan et al. New England Journal of Medicine profile →
  7. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
    2021 1.5k citations William J. Sandborn, Bruce E. Sands et al. Gastroenterology profile →
  8. Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis
    2017 1.2k citations William J. Sandborn, Bruce E. Sands et al. New England Journal of Medicine profile →
  9. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial
    2012 1.2k citations Wolfgang Hueber, Bruce E. Sands et al. Gut profile →
  10. ACG Clinical Guideline: Management of Crohn's Disease in Adults
    2018 903 citations Edward V. Loftus, Bruce E. Sands et al. profile →
  11. Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease
    2012 838 citations William J. Sandborn, Christopher Gasink et al. New England Journal of Medicine profile →
  12. Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis
    2019 787 citations Bruce E. Sands, William J. Sandborn et al. New England Journal of Medicine profile →
  13. Early Mucosal Healing With Infliximab Is Associated With Improved Long-term Clinical Outcomes in Ulcerative Colitis
    2011 693 citations Jean‐Frédéric Colombel, Paul Rutgeerts et al. Gastroenterology profile →
  14. The safety of vedolizumab for ulcerative colitis and Crohn's disease
    2016 563 citations Jean‐Frédéric Colombel, Bruce E. Sands et al. Gut profile →
  15. Effects of Vedolizumab Induction Therapy for Patients With Crohn’s Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed
    2014 531 citations Bruce E. Sands, Brian G. Feagan et al. Gastroenterology profile →
  16. Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis
    2019 461 citations Bruce E. Sands, Laurent Peyrin‐Biroulet et al. New England Journal of Medicine profile →
  17. Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS)
    2011 441 citations Simon Travis, Brian G. Feagan et al. Gut profile →
  18. Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials
    2017 296 citations Julián Panés, William J. Sandborn et al. Gut profile →
  19. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies
    2023 190 citations William J. Sandborn, Séverine Vermeire et al. profile →
  20. Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis
    2023 170 citations Geert D’Haens, Marla C. Dubinsky et al. New England Journal of Medicine profile →
  21. Guselkumab for the Treatment of Crohn’s Disease: Induction Results From the Phase 2 GALAXI-1 Study
    2022 132 citations William J. Sandborn, Geert D’Haens et al. Gastroenterology profile →
  22. New Therapeutics for Ulcerative Colitis
    2021 125 citations Bruce E. Sands et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Bruce E. Sands United States 82 28.6k 20.9k 10.8k 9.9k 4.5k 596 39.6k
Remo Panaccione Canada 81 26.4k 0.9× 19.4k 0.9× 10.1k 0.9× 8.2k 0.8× 4.4k 1.0× 704 36.7k
Gert Van Assche Belgium 92 26.9k 0.9× 20.6k 1.0× 10.7k 1.0× 8.9k 0.9× 3.2k 0.7× 476 36.8k
Geert D’Haens Netherlands 93 31.3k 1.1× 24.1k 1.2× 12.3k 1.1× 8.5k 0.9× 4.0k 0.9× 913 43.0k
Laurent Peyrin‐Biroulet France 107 34.1k 1.2× 25.1k 1.2× 13.3k 1.2× 9.9k 1.0× 6.4k 1.4× 1.2k 49.9k
Silvio Danese Italy 107 30.1k 1.1× 20.9k 1.0× 13.2k 1.2× 12.3k 1.2× 7.6k 1.7× 1.3k 50.7k
Stephen B. Hanauer United States 65 25.5k 0.9× 19.0k 0.9× 9.0k 0.8× 8.8k 0.9× 2.8k 0.6× 159 33.6k
Brian G. Feagan Canada 104 41.9k 1.5× 31.8k 1.5× 14.5k 1.3× 14.4k 1.5× 3.1k 0.7× 764 53.9k
Séverine Vermeire Belgium 121 35.6k 1.2× 26.1k 1.2× 12.6k 1.2× 14.3k 1.4× 10.6k 2.4× 1.3k 55.4k
Edward V. Loftus United States 98 26.3k 0.9× 21.5k 1.0× 13.7k 1.3× 4.8k 0.5× 2.1k 0.5× 773 37.2k
Jean‐Frédéric Colombel United States 111 42.0k 1.5× 31.8k 1.5× 16.2k 1.5× 12.7k 1.3× 7.9k 1.8× 714 58.7k

Countries citing papers authored by Bruce E. Sands

Since Specialization
Citations

This map shows the geographic impact of Bruce E. Sands's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bruce E. Sands with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bruce E. Sands more than expected).

Fields of papers citing papers by Bruce E. Sands

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bruce E. Sands. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bruce E. Sands. The network helps show where Bruce E. Sands may publish in the future.

Co-authorship network of co-authors of Bruce E. Sands

This figure shows the co-authorship network connecting the top 25 collaborators of Bruce E. Sands. A scholar is included among the top collaborators of Bruce E. Sands based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bruce E. Sands. Bruce E. Sands is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Danese, Silvio, Rupert W. Leong, Bruce E. Sands, et al.. (2025). Clinical Trial: Association Between Early Disease Clearance and Long‐Term Outcomes—4‐Year Results From the Phase 3 UNIFI Study of Ustekinumab in Ulcerative Colitis. Alimentary Pharmacology & Therapeutics. 62(5). 483–492.
2.
Jairath, Vipul, Geert D’Haens, Bruce E. Sands, et al.. (2025). Bowel Urgency in Crohn’s Disease: Effects of Mirikizumab in a Randomized Controlled Phase 3 Study. Clinical Gastroenterology and Hepatology. 24(2). 463–473.e5.
3.
Renard, Bernhard Y., Louis Cohen, Carmen Argmann, et al.. (2025). Disease duration impacts intestinal gene expression profiles in Crohn’s disease but not in ulcerative colitis. Journal of Crohn s and Colitis. 19(10).
4.
Vermeire, Séverine, Laurent Peyrin‐Biroulet, Silvio Danese, et al.. (2024). DOP12 Efficacy and safety of obefazimod in UC patients at weeks 48 and 96 of an open-label maintenance study among clinical responders at week 8 of the Phase 2b induction trial. Journal of Crohn s and Colitis. 18(Supplement_1). i94–i95. 1 indexed citations
5.
Ferrante, Marc, Silvio Danese, M Chen, et al.. (2024). OP05 Primary efficacy and safety of mirikizumab in moderate to severe Crohn’s Disease: results of the treat-through VIVID 1 study. Journal of Crohn s and Colitis. 18(Supplement_1). i7–i9. 11 indexed citations
6.
Magro, Fernando, Laurent Peyrin‐Biroulet, Bruce E. Sands, et al.. (2024). Endoscopic, Histologic, and Composite Endpoints in Patients With Ulcerative Colitis Treated With Etrasimod. Clinical Gastroenterology and Hepatology. 23(2). 341–350.e6. 3 indexed citations
7.
Gold, Stephanie, et al.. (2024). Dietary Interventions and Supplementation in Patients With an Ileal Pouch–Anal Anastomosis: A Systematic Review. Inflammatory Bowel Diseases. 31(1). 246–258. 4 indexed citations
8.
Panés, Julián, Geert D’Haens, Bruce E. Sands, et al.. (2024). Analysis of tofacitinib safety in ulcerative colitis from the completed global clinical developmental program up to 9.2 years of drug exposure. United European Gastroenterology Journal. 12(6). 793–801. 19 indexed citations
9.
10.
11.
Wils, Pauline, Vipul Jairath, Bruce E. Sands, et al.. (2023). Comparison of treatment effect between phase 2 and phase 3 trials in patients with inflammatory bowel disease. United European Gastroenterology Journal. 11(8). 797–806. 2 indexed citations
12.
Sands, Bruce E., Brian G. Feagan, Theresa Hunter, et al.. (2023). Mirikizumab Improves Quality of Life in Patients With Moderately-to-Severely Active Ulcerative Colitis: Results From the Phase 3 LUCENT-1 Induction and LUCENT-2 Maintenance Studies. Crohn s & Colitis 360. 5(4). otad070–otad070. 8 indexed citations
13.
Solitano, Virginia, David F. Schaeffer, Malcolm Hogan, et al.. (2023). Reliability and Responsiveness of Histologic Indices for the Assessment of Crohn’s Disease Activity. Clinical Gastroenterology and Hepatology. 22(9). 1898–1907.e25. 4 indexed citations
14.
Dubinsky, Marla C., Vipul Jairath, Brian G. Feagan, et al.. (2023). Changes in health-related quality of life and associations with improvements in clinical efficacy: a Phase 2 study of mirikizumab in patients with ulcerative colitis. BMJ Open Gastroenterology. 10(1). e001115–e001115. 8 indexed citations
15.
Peyrin‐Biroulet, Laurent, Edward V. Loftus, Jean‐Frédéric Colombel, et al.. (2021). Histologic Outcomes With Vedolizumab Versus Adalimumab in Ulcerative Colitis: Results From An Efficacy and Safety Study of Vedolizumab Intravenous Compared to Adalimumab Subcutaneous in Participants With Ulcerative Colitis (VARSITY). Gastroenterology. 161(4). 1156–1167.e3. 32 indexed citations
16.
Sands, Bruce E., Christopher Gasink, Lizhen Gao, et al.. (2017). OC-045 Efficacy & safety of dose adjustment & delayed response to ustekinumab in moderate–severe crohn’s disease patients: results from im-uniti maintenance study. HighWire Press Open Archive. A23.1–A23. 6 indexed citations
17.
Sandborn, William J., Paul Rutgeerts, Jean–Frédéric Colombel, et al.. (2017). Eldelumab [anti-interferon-γ-inducible protein-10 antibody] Induction Therapy for Active Crohn’s Disease: a Randomised, Double-blind, Placebo-controlled Phase IIa Study. Journal of Crohn s and Colitis. 11(7). 811–819. 27 indexed citations
18.
Colombel, Jean‐Frédéric, Bruce E. Sands, Paul Rutgeerts, et al.. (2016). The safety of vedolizumab for ulcerative colitis and Crohn's disease. Gut. 66(5). 839–851. 563 indexed citations breakdown →
19.
Sandborn, William J., Brian G. Feagan, Paul Rutgeerts, et al.. (2013). Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease. New England Journal of Medicine. 369(8). 711–721. 2011 indexed citations breakdown →
20.
Hueber, Wolfgang, Bruce E. Sands, Steve Lewitzky, et al.. (2012). Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut. 61(12). 1693–1700. 1156 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Remo Panaccione Breakdown of academic impact, for papers by Gert Van Assche Breakdown of academic impact, for papers by Geert D’Haens Breakdown of academic impact, for papers by Laurent Peyrin‐Biroulet Breakdown of academic impact, for papers by Silvio Danese Breakdown of academic impact, for papers by Stephen B. Hanauer Breakdown of academic impact, for papers by Brian G. Feagan Breakdown of academic impact, for papers by Séverine Vermeire Breakdown of academic impact, for papers by Edward V. Loftus Breakdown of academic impact, for papers by Jean‐Frédéric Colombel
Rankless by CCL
2026